PTP Pentixapharm Holding AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.…
Industry Peers
BiotechnologyKey Statistics
About Pentixapharm Holding (ETR: PTP)
›
Pentixapharm Holding (ETR: PTP) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 1.865 EUR on 19 November 2026, up 11.9% over 52 weeks. Its 52-week range is 1.300 EUR to 3.700 EUR: the price is 49.6% below the high and 43.5% above the low.
Its market capitalisation is 66.77M EUR.
Pentixapharm Holding reports return on equity of -47.1% and revenue down 91.2% year over year.
It holds more cash than debt, a net cash position of 3.59M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.